Mood stabilizers inhibit cytomegalovirus infection

Virology

Volumn 499, Issue , 2016, Pages 121-135

  Ornaghi, Sara ^a,b   Davis, John N ^a   Gorres, Kelly L ^a,c   Miller, George ^a   Paidas, Michael J ^a   van den Pol, Anthony N ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF WISCONSIN LA CROSSE   (United States)

Author keywords

Cytomegalovirus; Development; Mood stabilizers; Perinatal infection

Indexed keywords

GANCICLOVIR; GLYCOPROTEIN B; GREEN FLUORESCENT PROTEIN; HISTONE DEACETYLASE; MOOD STABILIZER; VALNOCTAMIDE; VALPROIC ACID; VALPROMIDE; AMIDE; TRANQUILIZER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BODY WEIGHT; CELL COUNTING; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC CONCENTRATION; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; EC50; FEMALE; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEWBORN; NONHUMAN; PERINATAL DEVELOPMENT; PRIORITY JOURNAL; REPORTER GENE; SELECTIVITY INDEX; SURVIVAL; VIRUS ATTACHMENT; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CELL LINE; CYTOMEGALOVIRUS; DISEASE MODEL; DRUG EFFECT; MORTALITY; MUROMEGALOVIRUS; PHYSIOLOGY; VIROLOGY;

AMIDES; ANIMALS; CELL LINE; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MUROMEGALOVIRUS; TRANQUILIZING AGENTS; VALPROIC ACID; VIRAL LOAD; VIRUS REPLICATION;

EID: 84987950363     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2016.09.012     Document Type: Article

References (60)

1. Barel, S., Yagen, B., Schurig, V., Soback, S., Pisani, F., Perucca, E., et al. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Clin. Pharmacol. Ther. 61:4 (1997), 442–449, 10.1016/s0009-9236(97)90194-6 (PubMed PMID: 9129561).
2. Bersudsky, Y., Applebaum, J., Gaiduk, Y., Sharony, L., Mishory, A., Podberezsky, A., et al. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar Disord. 12:4 (2010), 376–382, 10.1111/j.1399-5618.2010.00828.x (PubMed PMID: 20636634).
3. Bialer, M., Clinical pharmacology of valpromide. Clin. Pharmacokinet. 20:2 (1991), 114–122, 10.2165/00003088-199120020-00003 (PubMed PMID: 2029804).
4. Bialer, M., Haj-Yehia, A., Barzaghi, N., Pisani, F., Perucca, E., Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. Eur. J. Clin. Pharmacol. 38:3 (1990), 289–291 (Epub 1990/01/01. PubMed PMID: 2111246).
5. Bialer, M., Johannessen, S.I., Levy, R.H., Perucca, E., Tomson, T., White, H.S., Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 111 (2015), 85–141, 10.1016/j.eplepsyres.2015.01.001 (PubMed PMID: 25769377).
6. Brodie, M.J., Dichter, M.A., Antiepileptic drugs. N. Engl. J. Med. 334:3 (1996), 168–175, 10.1056/nejm199601183340308 (PubMed PMID: 8531974).
7. Brune, W., Hengel, H., Koszinowski U.H., 2001. A mouse model for cytomegalovirus infection. In: Coligan, John E., et al. (Eds.), Current Protocols in Immunology. Chapter 19: Unit 19.7. Epub 2008/04/25. 〈 http://dx.doi.org/10.1002/0471142735.im1907s43〉. (PubMed PMID: 18432758).
8. Chan, G.C., Yurochko, A.D., Analysis of cytomegalovirus binding/entry-mediated events. Methods Mol. Biol. 1119 (2014), 113–121, 10.1007/978-1-62703-788-4_8 (PubMed PMID: 24639221).
9. Cheeran, M.C., Lokensgard, J.R., Schleiss, M.R., Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin. Microbiol. Rev. 22:1 (2009), 99–126, 10.1128/cmr.00023-08 (PubMed PMID: 19136436; PubMed Central PMCID: PMCPMC2620634).
10. Compton, T., Nowlin, D.M., Cooper, N.R., Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 193:2 (1993), 834–841, 10.1006/viro.1993.1192 (PubMed PMID: 8384757).
11. Fujiki, R., Sato, A., Fujitani, M., Yamashita, T., A proapoptotic effect of valproic acid on progenitors of embryonic stem cell-derived glutamatergic neurons. Cell Death Dis., 4, 2013, e677, 10.1038/cddis.2013.205 (PubMed PMID: 23788034; PubMed Central PMCID: PMCPMC3702299).
12. Fukui, Y., Shindoh, K., Yamamoto, Y., Koyano, S., Kosugi, I., Yamaguchi, T., et al. Establishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay. Antimicrob. Agents Chemother. 52:7 (2008), 2420–2427, 10.1128/aac.00134-08 (PubMed PMID: 18458124; PubMed Central PMCID: PMCPMC2443885).
13. Gandhi, M.K., Khanna, R., Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 4:12 (2004), 725–738, 10.1016/s1473-3099(04)01202-2 (PubMed PMID: 1556712).
14. Gault, E., Michel, Y., Dehee, A., Belabani, C., Nicolas, J.C., Garbarg-Chenon, A., Quantification of human cytomegalovirus DNA by real-time PCR. J. Clin. Microbiol. 39:2 (2001), 772–775, 10.1128/jcm.39.2.772-775.2001 (PubMed PMID: 11158149; PubMed Central PMCID: PMCPMC87818).
15. Gorres, K.L., Daigle, D., Mohanram, S., McInerney, G.E., Lyons, D.E., Miller, G., Valpromide inhibits lytic cycle reactivation of epstein-barr virus. mBio, 7(2), 2016, 10.1128/mBio.00113-16 (PubMed PMID: 26933051; PubMed Central PMCID: PMCPMC4810481).
16. Guerrini, R., Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr. drugs 8:2 (2006), 113–129 (Epub 2006/04/13. PubMed PMID: 16608372).
17. Isaacson, M.K., Compton, T., Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. J. Virol. 83:8 (2009), 3891–3903, 10.1128/jvi.01251-08 (PubMed PMID: 19193805; PubMed Central PMCID: PMCPMC2663263).
18. Jarvis, M.A., Wang, C.E., Meyers, H.L., Smith, P.P., Corless, C.L., Henderson, G.J., et al. Human cytomegalovirus infection of caco-2 cells occurs at the basolateral membrane and is differentiation state dependent. J. Virol. 73:6 (1999), 4552–4560 (Epub 1999/05/11. PubMed PMID: 10233913; PubMed Central PMCID: PMCPMC112495).
19. Jennings, H.R., Romanelli, F., Comment: potential risk of valproic acid therapy in patients who are HIV-positive. Ann. Pharmacother. 34:11 (2000), 1348–1349 (Epub 2000/12/01. PubMed PMID: 11098354).
20. Kataoka, S., Takuma, K., Hara, Y., Maeda, Y., Ago, Y., Matsuda, T., Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid. Int. J. Neuropsychopharmacol. / Off. Sci. J. Coll. Int. Neuropsychopharmacol. (CINP) 16:1 (2013), 91–103, 10.1017/s1461145711001714 (PubMed PMID: 22093185).
21. Kuntz-Simon, G., Obert, G., Sodium valproate, an anticonvulsant drug, stimulates human cytomegalovirus replication. J. Gen. Virol. 76:Pt 6 (1995), 1409–1415, 10.1099/0022-1317-76-6-1409 (PubMed PMID: 7782769).
22. Mardivirin, L., Descamps, V., Lacroix, A., Delebassee, S., Ranger-Rogez, S., Early effects of drugs responsible for DRESS on HHV-6 replication in vitro. J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol. 46:3 (2009), 300–302, 10.1016/j.jcv.2009.08.006 (PubMed PMID: 19758840).
23. Matalon, S., Rasmussen, T.A., Dinarello, C.A., Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol. Med. 17:5–6 (2011), 466–472, 10.2119/molmed.2011.00076 (PubMed PMID: 21424110; PubMed Central PMCID: PMCPMC3105138).
24. Mawasi, H., Shekh-Ahmad, T., Finnell, R.H., Wlodarczyk, B.J., Bialer, M., Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide–amide derivatives of valproic acid. Epilepsy Behav.: EB 46 (2015), 72–78, 10.1016/j.yebeh.2015.02.040 (PubMed PMID: 25863940).
25. Mercorelli, B., Lembo, D., Palu, G., Loregian, A., Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives. Pharmacol. Ther. 131:3 (2011), 309–329, 10.1016/j.pharmthera.2011.04.007 (PubMed PMID: 21570424).
26. Michaelis, M., Kohler, N., Reinisch, A., Eikel, D., Gravemann, U., Doerr, H.W., et al. Increased human cytomegalovirus replication in fibroblasts after treatment with therapeutical plasma concentrations of valproic acid. Biochem. Pharmacol. 68:3 (2004), 531–538, 10.1016/j.bcp.2004.04.013 (PubMed PMID: 15242819).
27. Michaelis, M., Suhan, T., Reinisch, A., Reisenauer, A., Fleckenstein, C., Eikel, D., et al. Increased replication of human cytomegalovirus in retinal pigment epithelial cells by valproic acid depends on histone deacetylase inhibition. Invest. Ophthalmol. Vis. Sci. 46:9 (2005), 3451–3457, 10.1167/iovs.05-0369 (PubMed PMID: 16123451).
28. Mocarski, E.S., Shenk, T., Pass, R.F., Cytomegaloviruses. Fields, B.N., Knipe, D.M., Howley, P.M., (eds.) Fields Virology. 2, 2007, Lippincott, Williams & Wilkins, Philadelphia, PA, 2702–2751.
29. Monti, B., Polazzi, E., Contestabile, A., Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr. Mol. Pharmacol. 2:1 (2009), 95–109 (Epub 2009/12/22. PubMed PMID: 20021450).
30. Moog, C., Kuntz-Simon, G., Caussin-Schwemling, C., Obert, G., Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. J. Gen. Virol. 77:Pt 9 (1996), 1993–1999, 10.1099/0022-1317-77-9-1993 (PubMed PMID: 8810995).
31. Nakashima, H., Kaufmann, J.K., Wang, P.Y., Nguyen, T., Speranza, M.C., Kasai, K., et al. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. J. Clin. Investig. 125:11 (2015), 4269–4280, 10.1172/jci80713 (PubMed PMID: 26524593; PubMed Central PMCID: PMCPMC4639993).
32. Nau, H., Hauck, R.S., Ehlers, K., Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol. Toxicol. 69:5 (1991), 310–321 (Epub 1991/11/01. PubMed PMID: 1803343).
33. Okada, A., Kurihara, H., Aoki, Y., Bialer, M., Fujiwara, M., Amidic modification of valproic acid reduces skeletal teratogenicity in mice. Birth Defects Res. Part B: Dev. Reprod. Toxicol. 71:1 (2004), 47–53, 10.1002/bdrb.10057 (PubMed PMID: 14991910).
34. Otsuki, A., Patel, A., Kasai, K., Suzuki, M., Kurozumi, K., Chiocca, E.A., et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol. Ther.: J. Am. Soc. Gene Ther. 16:9 (2008), 1546–1555, 10.1038/mt.2008.155 (PubMed PMID: 18648350).
35. Paglino, J.C., van den Pol, A.N., Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J. Virol. 85:18 (2011), 9346–9358, 10.1128/jvi.00723-11 (PubMed PMID: 21734048; PubMed Central PMCID: PMCPMC3165768).
36. Paradis, F.H., Hales, B.F., Exposure to valproic acid inhibits chondrogenesis and osteogenesis in mid-organogenesis mouse limbs. Toxicol. Sci.: Off. J. Soc. Toxicol. 131:1 (2013), 234–241, 10.1093/toxsci/kfs292 (PubMed PMID: 23042728; PubMed Central PMCID: PMCPMC3537135).
37. Perucca, E., Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16:10 (2002), 695–714 (Epub 2002/09/25. PubMed PMID: 12269862).
38. Phiel, C.J., Zhang, F., Huang, E.Y., Guenther, M.G., Lazar, M.A., Klein, P.S., Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276:39 (2001), 36734–36741, 10.1074/jbc.M101287200 (PubMed PMID: 11473107).
39. Pisani, F., Fazio, A., Oteri, G., Di Perri, R., Dipropylacetic acid plasma levels; diurnal fluctuations during chronic treatment with dipropylacetamide. Ther. Drug Monit. 3:3 (1981), 297–301 (Epub 1981/01/01. PubMed PMID: 6798719).
40. Pisani, F., Fazio, A., Oteri, G., Ruello, C., Gitto, C., Russo, F., et al. Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients. Epilepsia 27:5 (1986), 548–552 (PubMed PMID: 3093212).
41. Radatz, M., Ehlers, K., Yagen, B., Bialer, M., Nau, H., Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res. 30:1 (1998), 41–48 (Epub 1998/04/29. PubMed PMID: 9551843).
42. Ramsburg, E., Publicover, J., Buonocore, L., Poholek, A., Robek, M., Palin, A., et al. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. J. Virol. 79:24 (2005), 15043–15053, 10.1128/jvi.79.24.15043-15053.2005 (PubMed PMID: 16306575; PubMed Central PMCID: PMCPMC1316007).
43. Scattoni, M.L., Gandhy, S.U., Ricceri, L., Crawley, J.N., Unusual repertoire of vocalizations in the BTBR T+tf/J mouse model of autism. PloS One, 3(8), 2008, e3067, 10.1371/journal.pone.0003067 (PubMed PMID: 18728777; PubMed Central PMCID: PMCPMC2516927).
44. Shaw, R.N., Arbiser, J.L., Offermann, M.K., Valproic acid induces human herpesvirus 8 lytic gene expression in BCBL-1 cells. AIDS 14:7 (2000), 899–902 (Epub 2000/06/06. PubMed PMID: 10839602).
45. Shekh-Ahmad, T., Mawasi, H., McDonough, J.H., Yagen, B., Bialer, M., The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy Behav.: EB 49 (2015), 298–302, 10.1016/j.yebeh.2015.04.012 (PubMed PMID: 25979572).
46. Shekh-Ahmad, T., Hen, N., Yagen, B., McDonough, J.H., Finnell, R.H., Wlodarczyk, B.J., et al. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia 55:2 (2014), 353–361, 10.1111/epi.12480 (PubMed PMID: 24313671).
47. Slavuljica, I., Kvestak, D., Huszthy, P.C., Kosmac, K., Britt, W.J., Jonjic, S., Immunobiology of congenital cytomegalovirus infection of the central nervous system-the murine cytomegalovirus model. Cell. Mol. Immunol. 12:2 (2015), 180–191, 10.1038/cmi.2014.51 (PubMed PMID: 25042632; PubMed Central PMCID: PMCPMC4654296).
48. Spampanato, J., Dudek, F.E., Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus. Epilepsia 55:9 (2014), e94–e98, 10.1111/epi.12702 (PubMed PMID: 24995528; PubMed Central PMCID: PMCPMC4167227).
49. Stepansky, W., A clinical study in the use of valmethamide, an anxiety-reducing drug. Curr. Ther. Res., Clin. Exp. 2 (1960), 144–147 (PubMed PMID: 13834349).
50. Tsutsui, Y., Effects of cytomegalovirus infection on embryogenesis and brain development. Congenit. Anom. 49:2 (2009), 47–55, 10.1111/j.1741-4520.2009.00222.x (PubMed PMID: 19489954).
51. Tung, E.W., Winn, L.M., Epigenetic modifications in valproic acid-induced teratogenesis. Toxicol. Appl. Pharmacol. 248:3 (2010), 201–209, 10.1016/j.taap.2010.08.001 (PubMed PMID: 20705080).
52. van den Pol, A.N., Dalton, K.P., Rose, J.K., Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J. Virol. 76:3 (2002), 1309–1327 (Epub 2002/01/05. PubMed PMID: 11773406; PubMed Central PMCID: PMCPMC135838).
53. van den Pol, A.N., Mocarski, E., Saederup, N., Vieira, J., Meier, T.J., Cytomegalovirus cell tropism, replication, and gene transfer in brain. J. Neurosci.: Off. J. Soc. Neurosci. 19:24 (1999), 10948–10965 (Epub 1999/12/14. PubMed PMID: 10594076).
54. Varghese, F.S., Kaukinen, P., Glasker, S., Bespalov, M., Hanski, L., Wennerberg, K., et al. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antivir. Res. 126 (2016), 117–124, 10.1016/j.antiviral.2015.12.012 (PubMed PMID: 26752081).
55. Vieira, J., Schall, T.J., Corey, L., Geballe, A.P., Functional analysis of the human cytomegalovirus US28 gene by insertion mutagenesis with the green fluorescent protein gene. J. Virol. 72:10 (1998), 8158–8165 (Epub 1998/09/12. PubMed PMID: 9733857; PubMed Central PMCID: PMCPMC110158).
56. Winkler, I., Blotnik, S., Shimshoni, J., Yagen, B., Devor, M., Bialer, M., Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Br. J. Pharmacol. 146:2 (2005), 198–208, 10.1038/sj.bjp.0706310 (PubMed PMID: 15997234; PubMed Central PMCID: PMCPMC1576263).
57. Witvrouw, M., Schmit, J.C., Van Remoortel, B., Daelemans, D., Este, J.A., Vandamme, A.M., et al. Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro. AIDS Res. Hum. Retrovir. 13:2 (1997), 187–192, 10.1089/aid.1997.13.187 (PubMed PMID: 9007204).
58. Wlodarczyk, B.J., Ogle, K., Lin, L.Y., Bialer, M., Finnell, R.H., Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice. Bipolar Disord. 17:6 (2015), 615–625, 10.1111/bdi.12325 (PubMed PMID: 26292082; PubMed Central PMCID: PMCPMC4631615).
59. Wollmann, G., Drokhlyansky, E., Davis, J.N., Cepko, C., van den Pol, A.N., Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors. J. Virol. 89:13 (2015), 6711–6724, 10.1128/jvi.00709-15 (PubMed PMID: 25878115; PubMed Central PMCID: PMCPMC4468483).
60. Zurbach, K.A., Moghbeli, T., Snyder, C.M., Resolving the titer of murine cytomegalovirus by plaque assay using the M2-10B4 cell line and a low viscosity overlay. Virol. J., 11, 2014, 71, 10.1186/1743-422x-11-71 (PubMed PMID: 24742045; PubMed Central PMCID: PMCPMC4006460).